ADVFN Logo ADVFN

Não encontramos resultados para:
Verifique se escreveu corretamente ou tente ampliar sua busca.

Tendências Agora

Rankings

Parece que você não está logado.
Clique no botão abaixo para fazer login e ver seu histórico recente.

Cadastre-se

Já é membro? Faça login

Moneta Markets

Abrir Conta

Moneta Markets
Dados
Notícias
Ferramentas
Mercados
Comunidade

Recursos principais

Follow Feed

Conecte-se com traders e investidores em nossa comunidade Follow Feed.

Fluxo de Opções

Explore dados abrangentes de opções e utilize filtros avançados com Fluxo de Opções.

Monitor

Organize e monitore sua lista de ações e ativos com o Monitor.
AI Entrar Premium IconPremium Help Menu
Índice Bovespa
121.077,50
0,26%
S&P 500
6.037,59
1,06%
US Dollar vs BRL
6,7426
0,00%
Bitcoin
95.632,92
-0,06%
Brent Oil
72,785
-0,14%
As Melhores Corretoras Online
Registration Strip Icon for smarter Negocie de forma mais inteligente, não mais difícil: Libere seu potencial com nosso conjunto de ferramentas e discussões ao vivo.
Cadastre-se
  1. Início
  2. Investir
  3. Ações
  4. EUA
  5. NASDAQ
  6. Contineum Therapeutics Inc (CTNM)

  7. Contineum Therapeutics Inc (CTNM) Notícias

CTNM

Contineum Therapeutics (CTNM)

Contineum Therapeutics Inc
De:
Ordenação:
 Apresentando as notícias mais relevantes sobre:NASDAQ:CTNM
DataHoraFonteTítuloCódigoCompanhia
16/12/202418:05Business WireContineum Therapeutics Initiates Patient Dosing in Phase 1b Positron Emission Tomography (PET) Trial of PIPE-791NASDAQ:CTNMContineum Therapeutics Inc
27/11/202419:06Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:CTNMContineum Therapeutics Inc
25/11/202410:05Business WireContineum Therapeutics to Attend the 7th Annual Evercore HealthCONx ConferenceNASDAQ:CTNMContineum Therapeutics Inc
18/11/202419:05Edgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNASDAQ:CTNMContineum Therapeutics Inc
18/11/202410:05Business WireContineum Therapeutics Expands Clinical Development of PIPE-791 With FDA Authorization of Its Investigational New Drug (IND) Application for Chronic PainNASDAQ:CTNMContineum Therapeutics Inc
13/11/202418:05Business WireContineum Therapeutics to Attend Upcoming Investor ConferencesNASDAQ:CTNMContineum Therapeutics Inc
06/11/202418:10Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:CTNMContineum Therapeutics Inc
06/11/202418:08Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:CTNMContineum Therapeutics Inc
06/11/202418:05Business WireContineum Therapeutics Reports Third Quarter 2024 Financial Results and Recent Business HighlightsNASDAQ:CTNMContineum Therapeutics Inc
28/08/202417:05Business WireContineum Therapeutics to Present at Multiple Upcoming Investor ConferencesNASDAQ:CTNMContineum Therapeutics Inc
14/08/202413:19Edgar (US Regulatory)Form 8-K/A - Current report: [Amend]NASDAQ:CTNMContineum Therapeutics Inc
13/08/202417:05Business WireContineum Therapeutics Reports Second Quarter 2024 Financial Results and Recent Business HighlightsNASDAQ:CTNMContineum Therapeutics Inc
31/07/202417:05Business WireContineum Therapeutics Announces Publication of Encouraging Data in the Proceedings of the National Academy of Sciences on PIPE-307, Its M1 Receptor Selective Inhibitor, in Clinical Development for Relapse-Remitting Multiple SclerosisNASDAQ:CTNMContineum Therapeutics Inc
24/06/202417:05Business WireContineum Therapeutics Announces Appointment of Sarah Boyce to Board of DirectorsNASDAQ:CTNMContineum Therapeutics Inc
04/06/202417:05Business WireContineum Therapeutics to Present at the 45th Annual Goldman Sachs Healthcare ConferenceNASDAQ:CTNMContineum Therapeutics Inc
03/06/202418:43Edgar (US Regulatory)Form 3 - Initial statement of beneficial ownership of securitiesNASDAQ:CTNMContineum Therapeutics Inc
03/06/202417:05Business WireContineum Therapeutics Announces Appointment of John Healy as General Counsel & Corporate SecretaryNASDAQ:CTNMContineum Therapeutics Inc
20/05/202417:05Business WireContineum Therapeutics Announces Appointment of Troy Ignelzi to Board of DirectorsNASDAQ:CTNMContineum Therapeutics Inc
16/05/202417:05Business WireContineum Therapeutics Reports First Quarter 2024 Financial Results and Recent Business HighlightsNASDAQ:CTNMContineum Therapeutics Inc
04/04/202422:02GlobeNewswire Inc.Contineum Therapeutics Announces Pricing of Initial Public OfferingNASDAQ:CTNMContineum Therapeutics Inc
 Apresentando as notícias mais relevantes sobre:NASDAQ:CTNM

Seu Histórico Recente

BOV
IBOV
Índice Bovespa
BOV
BRAV3
Brava Energia ON
BOV
AERI3
Aeris Industria E Comerc... ON
BOV
CSAN3
COSAN ON
BOV
FICT3
Fictor Alimentos ON
BOV
GFSA3
GAFISA ON
BOV
MGLU3
MAGAZINE LUIZA ON
BOV
AZEV4
AZEVEDO PN
BOV
RAIZ4
Raizen S.A PN
BOV
RCSL4
RECRUSUL PN
BOV
COGN3
COGNA ON
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

Brasil
Empresa
Negócios
Popular
Obter o aplicativo
App Store
Google Play

Suporte: (11) 4950 5808 | suporte@advfn.com.br

Ao acessar os serviços da ADVFN você estará de acordo com os Termos e Condições

© 2024 ADVFN PLC - Todos os direitos reservados